Serum levels of IL-33 is increased in patients with ankylosing spondylitis


Interleukin-33 (IL-33) is implicated in rheumatoid arthritis with effects of promoting tumor necrosis factor-alpha (TNF-α) and interleukin-17 (IL-17) productions, which have been demonstrated to play a pivotal role in ankylosing spondylitis (AS). However, changes of IL-33 levels and its effects in AS have not been investigated. Eighty-nine and 178 healthy controls were included in the current study. Erythrocyte sedimentation rate, serum levels of C-reactive protein, IL-17, and IL-33 were determined. Effects of IL-33 on TNF-α and IL-6 productions were investigated. Effects of IL-33 on neutrophil migration were also evaluated. Serum levels of IL-33 were elevated in AS patients. Moreover, IL-33 was significantly higher in active AS patients according to Bath Ankylosing Spondylitis Disease Activity Index. IL-33 concentrations in serum were positively correlated with TNF-α and IL-17 levels (IL-33 and TNF-α, r = 0.54, P < 0.01; IL-33 and IL-17, r = 0.47, P < 0.01). IL-33 dose-dependently enhanced TNF-α and IL-6 productions by peripheral blood mononuclear cells (PBMCs) responding to lipopolysaccharide. IL-33 induced neutrophil migration only in higher doses (≥10 ng/ml). Serum levels of IL-33 were elevated in AS patients. IL-33 may play a role in AS development via enhancing TNF-α production by PBMCs and inducing neutrophil migration.

DOI: 10.1007/s10067-011-1843-x

3 Figures and Tables


Citations per Year

166 Citations

Semantic Scholar estimates that this publication has 166 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Han2011SerumLO, title={Serum levels of IL-33 is increased in patients with ankylosing spondylitis}, author={Guo-Wei Han and L Zeng and Chun-Xiang Liang and B O Cheng and Bing-Sheng Yu and Hao-miao Li and F. F. Zeng and Shao-Yu Liu}, journal={Clinical Rheumatology}, year={2011}, volume={30}, pages={1583-1588} }